Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
Type:
Application
Filed:
December 19, 2023
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
James Thomas KOERBER, Wyne Pun LEE, Tangsheng YI, Juan ZHANG, Cary Dean AUSTIN, Cecilia P.C. CHIU, Joseph Edward CHAVARRIA-SMITH, Jawahar SUDHAMSU
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
January 11, 2024
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
Type:
Application
Filed:
November 13, 2023
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
Paul Gibbons, Emily Hanan, Wendy Liu, Joseph Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
April 20, 2023
Date of Patent:
May 7, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
Type:
Grant
Filed:
April 19, 2022
Date of Patent:
April 30, 2024
Assignee:
Genentech, Inc.
Inventors:
Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
April 20, 2023
Publication date:
April 25, 2024
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Type:
Grant
Filed:
August 3, 2021
Date of Patent:
April 23, 2024
Assignee:
Genentech, Inc.
Inventors:
Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
Abstract: The present disclosure relates to techniques for segmenting objects within medical images using a deep learning network that is localized with object detection based on a derived contrast mechanism. Particularly, aspects are directed to localizing an object of interest within a first medical image having a first characteristic, projecting a bounding box or segmentation mask of the object of interest onto a second medical image having a second characteristic to define a portion of the second medical image, and inputting the portion of the second medical image into a deep learning model that is constructed as a detector using a weighted loss function capable of segmenting the portion of the second medical image and generating a segmentation boundary around the object of interest. The segmentation boundary may be used to calculate a volume of the object of interest for determining a diagnosis and/or a prognosis of a subject.
Type:
Grant
Filed:
February 7, 2022
Date of Patent:
April 23, 2024
Assignee:
Genentech, Inc.
Inventors:
Luke Xie, Kai Henrik Barck, Omid Bazgir
Abstract: The present disclosure provides liquid formulations comprising polypeptides and surfactants. In particular, it discloses a liquid formulation comprising a polypeptide and a surfactant, wherein at least about 70% (wt %) of the surfactant are isosorbide polyoxyethylene (POE) fatty acid esters. The invention also provides methods for making such liquid formulations, articles of manufacture comprising such liquid formulations and methods of treating a patient with such liquid formulations.
Type:
Application
Filed:
December 6, 2023
Publication date:
April 18, 2024
Applicant:
Genentech, Inc.
Inventors:
Anthony TOMLINSON, Barthelemy Luc DEMEULE, Isidro Angelo Eleazar ZARRAGA
Abstract: Techniques disclosed herein relate to inferring a type of multiple sclerosis and determining whether to output an alert based on codes detected within noisy assessment data corresponding to a subject. The noisy assessment data includes content originating from a care provider that identifies a characteristic of the subject or of a treatment for the subject, and the subject has been diagnosed with multiple sclerosis. A temporal dynamic or distribution is determined based on instances of the code detection, and a modulation is determined based on the temporal dynamic or the distribution. It is determined whether an alert criterion is satisfied based on whether the modulation is above a threshold so as to represent noise or a predicted transition across types of multiple sclerosis. The inferred type of multiple sclerosis is output. When the alert criterion is satisfied, an alert is output as well.
Type:
Application
Filed:
November 10, 2023
Publication date:
April 18, 2024
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC.
Inventors:
Shemra Rizzo, Kelly Anne Zalocusky, Katherine Anne Belendiuk, Nicole Gidaya Bonine, Yifeng Chia, Laura Gaetano, Ryan William Gan, Jumaah Ingram Goldberg, Xiaoming Jia
Abstract: The present disclosure relates to techniques for service to service communication and authentication via a network mesh. Particularly, aspects are directed to receiving, at a network mesh, a service request for a first service, and obtaining information associated with the first service. The information includes a location of a first pod encapsulating the first service. The network mesh using the location of the first pod, retrieves security rules specific for the first pod. The network mesh forwards the service request to the first service based on the security rules of the first pod and obtains results of the service request from the first service. The results include a sub result obtained from a second service in accordance with security rules for the first pod encapsulating the first service and security rules for a second pod encapsulating the second service.
Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Type:
Application
Filed:
October 18, 2023
Publication date:
April 11, 2024
Applicants:
GENENTECH, INC., CURIS, INC
Inventors:
Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
Abstract: Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.
Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Application
Filed:
November 10, 2023
Publication date:
April 4, 2024
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
Inventors:
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Abstract: Provided herein are antibodies that bind to a peptide of an N-terminally ubiquitinated polypeptide and methods of screening for such antibodies. Also provided herein are detection and enrichment methods using such antibodies for detecting or enriching a peptide of an N-terminally ubiquitinated polypeptide.
Type:
Application
Filed:
December 12, 2023
Publication date:
April 4, 2024
Applicant:
Genentech, Inc.
Inventors:
Donald Scott KIRKPATRICK, James Thomas KOERBER, Christopher Williamson DAVIES
Abstract: Methods are provided to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
Type:
Application
Filed:
November 20, 2023
Publication date:
April 4, 2024
Applicant:
Genentech, Inc.
Inventors:
Martine Darwish, Surinder Kaur, Dian Su, Keyang Xu
Abstract: Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane,
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
April 2, 2024
Assignee:
Genentech, Inc.
Inventors:
Jerome Joseph Bill, Jr., Arick Michael Brown, Christopher John Dowd, Brooke Ellen Thayer